MDxHealth SA (MDXH) 주식 분석

회사 개요

MDxHealth SA is a commercial-stage precision diagnostics enterprise that specializes in providing urologic solutions across the United States, Europe, and international markets. The company's core offerings include testing solutions such as Select mdx, a non-invasive urine test designed to measure the expression of two mRNA cancer-related biomarkers for prostate cancer. This business model places MDxHealth within the Healthcare sector, specifically operating in the Diagnostics & Research industry, where the focus is on developing advanced tools for disease detection and research rather than direct pharmaceutical production. The company currently maintains a market capitalization of $106.32M and generates annual revenue of $107.88M, while specific employee count data is not publicly disclosed in the available records. These valuation and revenue figures indicate that MDxHealth operates as a mid-cap entity with a revenue stream that significantly exceeds its market cap, suggesting a high proportion of intangible assets, early-stage growth, or potential dilution history relative to its current equity valuation.

재무 건전성

The company reported trailing twelve-month revenue of $107.88M, yet it simultaneously recorded a net income loss of $33,519,000 and an EBITDA of $-7,059,000, revealing a substantial disconnect between top-line sales generation and bottom-line profitability. This wide gap between revenue and net income highlights a cost structure where operating expenses, likely driven by research and development or commercialization costs, consume the majority of gross proceeds before reaching the operating income stage. Free cash flow stands at $-3,658,000, indicating that the company is currently burning cash through its operations and investing heavily in growth initiatives, which limits immediate financial flexibility but is typical for commercial-stage biotech firms. Profitability metrics further illustrate this challenge, with a gross margin of 64.5% demonstrating efficient cost of goods sold, contrasted by a negative operating margin of -17.8% and a profit margin of -31.1% that reflect high overhead relative to sales. The balance sheet shows a cash position of $29.14M against total debt of $86.60M, meaning the firm holds significantly less liquid assets than its debt obligations, although the debt-to-equity ratio is listed as N/A due to the financial structure. The current ratio is 1.08, suggesting that the company's current assets barely exceed its current liabilities, indicating a tight but technically solvent short-term liquidity position. Return on Equity is reported at -2440.4% and Return on Assets at -5.9%, figures that mathematically reflect the heavy losses against the existing equity base and asset book value, signaling that management has not yet generated returns sufficient to offset capital deployment.

밸류에이션 평가

Valuation multiples for MDxHealth reflect its unprofitable status, with a trailing P/E ratio of N/A and a forward P/E of -15.92, implying that the market prices the stock based on anticipated future earnings recovery rather than historical profitability. The price-to-book ratio is -9.00, a negative figure that indicates the market values the company at a discount to its book value, often seen in distressed or highly speculative biotech stocks where assets are undervalued on the balance sheet. Additionally, the price-to-sales ratio of 0.99 and an EV/EBITDA of -23.20 provide alternative lenses, suggesting that investors are willing to pay nearly one dollar of revenue for every dollar of sales, despite the negative enterprise value multiples driven by the debt load. Price action over the past year shows a 52-week high of $5.33 and a 52-week low of $1.36, placing the current trading price within a wide volatility range that reflects significant market sentiment shifts. The beta value is -537543.56, an extreme statistical anomaly that suggests a severe data error or systemic calculation issue in the source, as a beta cannot logically be negative to this magnitude in standard market terms, though it technically indicates a relationship to the broader market that defies conventional volatility interpretation.

Growth & Income

Revenue growth for the trailing twelve months stands at 19.4%, demonstrating strong top-line expansion, whereas earnings growth is listed as N/A due to the company's persistent net losses. Since earnings growth is not positive, the company is not growing earnings faster than revenue; instead, it is expanding sales while managing losses, a common dynamic in the growth phase of diagnostic companies. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means all available cash flow is retained within the business to fund operations, R&D, or debt reduction rather than being distributed to shareholders. Consequently, MDxHealth's profile is defined by aggressive revenue expansion funded by internal cash reserves and external capital markets, with no current income generation for investors through dividend payouts.